킵스파마
Financials
Valuation Metrics
킵스파마's Market Cap is ₩1191B. At end of 2025 it was ₩2088B. Ranked #1119 of 2,436 in KR market (top 46%), #574 of 1,649 on KOSDAQ (top 35%), #120 of 214 in Semiconductors & Semiconductor Equipment (top 56%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 119.06B KRW | KR#1,119/2,436 Sec#120/214 |
| Revenue | 188.94B KRW | KR#1,053/2,436 Sec#73/214 |
| Net Income | -3.25B KRW | KR—/2,436 Sec—/214 |
| Total Assets | 243.88B KRW | KR#1,140/2,436 Sec#92/214 |
| Net Assets | 85.23B KRW | KR#1,509/2,436 Sec#132/214 |
| Employees | 27 | KR#2,192/2,436 Sec#203/214 |
| Value | ||
| P/B | 1.40x | KR#1,746/2,436 Sec#108/214 |
| P/S | 0.63x | KR#1,081/2,436 Sec#46/214 |
| EV/EBITDA | 229.84x | KR#1,529/2,436 Sec#125/214 |
| FCF Yield | -39.35% | KR—/2,436 Sec—/214 |
| Profitability | ||
| ROE | -3.81% | KR#1,706/2,436 Sec#140/214 |
| ROA | -1.33% | KR#1,638/2,436 Sec#138/214 |
| Op. Margin | 0.43% | KR#1,556/2,436 Sec#130/214 |
| Revenue Growth | 46.23% | KR#325/2,436 Sec#58/214 |
| Earnings Growth | -744.19% | KR#1,670/2,436 Sec#132/214 |
| Financial Health | ||
| Debt Ratio | 286.14% | KR#2,106/2,436 Sec#191/214 |
| Total Debt | 92.11B KRW | KR#743/2,436 Sec#44/214 |
| FCF | -46.85B KRW | KR#2,081/2,436 Sec#190/214 |
| Cash | 22.30B KRW | KR#1,178/2,436 Sec#106/214 |
| Current Ratio | 1.26x | KR#1,513/2,436 Sec#148/214 |
| Net Debt/EBITDA | 84.95x | KR#1,560/2,436 Sec#130/214 |
| Performance | ||
| 1Y Return | -55.25% | KR#2,178/2,436 Sec#205/214 |
| 1M Return | -2.95% | KR#1,371/2,436 Sec#43/214 |
| From 52W High | -58.79% | KR#1,676/2,436 Sec#142/214 |
| 1Y MDD | -73.84% | KR#2,097/2,436 Sec#183/214 |
| Trading | ||
| Volume | 40,637 shares | KR#1,387/2,436 Sec#161/214 |
| Foreign Own. | 2.42% | KR—/2,436 Sec—/214 |
| Per Share | ||
| EPS | -120 KRW | KR—/2,436 Sec—/214 |
| BPS | 3,319 KRW | KR#1,745/2,436 Sec#156/214 |
Company Info
KeepsPharma, established in 2000 and headquartered in Hwaseong-si, Gyeonggi-do, transitioned to the pharmaceutical and biotechnology sector in 2025, following its KOSDAQ listing in 2017. The company's primary activities include the manufacturing and sales of specialized medicines, development of oral peptide drug delivery platforms, anticancer treatments, and medical devices. KeepsPharma is also diversifying its business through the expansion of CDMO and CMO services, LFP recycling, and the localization of micro OLED equipment and fine metal masks.